How can I tell whether a joint treatment may help?

What does “does stem cell therapy work” mean for me?

The answer depends on which joint hurts and what goes into the shot. Results from a blood-based treatment don't answer every question about marrow-based care because their contents differ.

Ask whether people with similar soreness walked, slept or climbed stairs more easily after returning to usual activity. Then ask how often they got little relief, what aftercare they needed and how long relief lasted.

Research can't predict exactly what will happen in your joint. An exam helps connect those broad results to your soreness before you pay for any proposed treatment.

How will a visit help me weigh the evidence?

QC Kinetix discusses regenerative treatments, or non-surgical care prepared there from your blood or marrow. The clinician can compare your exam and prior X-ray with the choices offered.

Ask what the treatment may not help, when improvement may appear and what recovery involves. You'll also want the entire price and every expected follow-up visit in writing.

What result matters in daily life?

A lower pain score matters less if stairs, sleep or walking haven't changed. Pick one daily task and record how hard it feels before treatment.

Ask when you'll test that same task again after normal activity resumes. If it hasn't improved, ask whether more time, different care or another exam makes sense.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

3. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

4. FDA's final guidance for industry, issued July 2020 by CBER and CDRH under docket FDA-2017-D-6146, sets out how the agency applies the minimal manipulation and homologous use criteria that determine whether a cell or tissue product is a 361 HCT/P or an unapproved 351 biological product requiring a license.

   US Food and Drug Administration, CBER and CDRH — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff. , 2020.

5. A double-blind randomized trial testing whether adding bone marrow aspirate concentrate to arthroscopic partial meniscectomy improves outcomes in patients with early knee osteoarthritis used the IKDC score at one year as its primary endpoint, with Kellgren-Lawrence grade as a radiographic secondary.

   Yanke AB, et al. — A Prospective, Randomized, Double-Blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate During Arthroscopic Meniscectomy in Patients With Early Knee Osteoarthritis. Am J Sports Med, 2024. DOI: 10.1177/03635465241275647.

6. A 2024 systematic review of bone marrow aspirate concentrate for HIP osteoarthritis found the clinical evidence base thinner than for the knee, with most studies uncontrolled - the joint matters, and evidence does not transfer across joints.

   Chandrashekar S, et al. — Safety and Efficacy of Bone-Marrow Aspirate Concentrate in Hip Osteoarthritis: A Systematic Review of Current Clinical Evidence. Indian J Orthop, 2024. DOI: 10.1007/s43465-024-01183-7.

7. A multicenter crossover randomized controlled trial randomized 40 patients with discogenic chronic low back pain to saline trigger point injection, intradiscal PRP, or intradiscal bone marrow concentrate with 12-month follow-up - one of very few controlled spine trials in this field, and it enrolled 40 people.

   Navani A, et al. — The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up. Pain Physician, 2024.